Multiple Myeloma Hub

57 Episodes

1. How can we use the microbiome to improve cancer immunotherapy and alleviate side effect such as graft-versus-host-disease

   Published: 7/8/2020
2. Melphalan flufenamide (melflufen) + novel agents for RRMM

   Published: 7/8/2020
3. Isatuximab plus KRd for high-risk NDMM

   Published: 6/24/2020
4. Novel approaches in multiple myeloma: what is unique about CELMoDs?

   Published: 6/24/2020
5. Hot topics in MM: quadruplets and anti-BCMA therapy

   Published: 6/24/2020
6. Genomics of high-risk myeloma

   Published: 6/23/2020
7. The association between the diversity of the oral microbiome and PFS

   Published: 6/22/2020
8. Novel approaches in multiple myeloma: BFCR4350A

   Published: 6/18/2020
9. Update from CARTITUDE-1 | What's new since ASH?

   Published: 6/8/2020
10. Novel approaches in multiple myeloma: TAK-079

    Published: 6/4/2020
11. Should we use KRd or VRd for patients with NDMM?

    Published: 6/4/2020
12. What is the optimal treatment for bone lesions, including patients with renal insufficiency?

    Published: 6/3/2020
13. Recent advances in our understanding of myeloma progression

    Published: 6/2/2020
14. Quadruplet combinations in transplant-ineligible NDMM: isatuximab + Vd + cyclo or len

    Published: 6/1/2020
15. How I treat elderly patients with NDMM

    Published: 5/28/2020
16. Understanding resistance mechanisms to current standard of care and how to overcome them

    Published: 5/19/2020
17. What is plasma cell leukemia and what are the latest advances in treatment?

    Published: 5/15/2020